Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Response to DEFRA consultation

28th Jan 2026 07:08

RNS Number : 7031Q
CVS Group plc
28 January 2026
 

28 January 2026

 

CVS GROUP plc

("CVS" or the "Company" and, together with its subsidiaries, the "Group")

 

Response to DEFRA consultation on the Veterinary Surgeons Act 1966

 

CVS welcomes the announcement by the Department for Environment, Food and Rural Affairs (DEFRA) that they will be commencing a consultation on proposed reforms to the Veterinary Surgeons Act 1966 (VSA).

 

Reform of the VSA was a remedy recommended by the Competition and Markets Authority (CMA), along with price transparency, in its October 2025 provisional decision of its market investigation into veterinary services for household pets in the UK and the Government had previously announced its intention to consult on this.

 

CVS has been calling for reform to the VSA for some time and has engaged with both DEFRA and the CMA during the market investigation to share its views on these expected reforms. CVS believes reform will help strengthen consumer confidence in the profession, ensure enhanced regulation including practice level accountability for maintaining appropriate standards such as mandatory compliance with the voluntary Practice Standards Scheme (PSS) which CVS practices embrace. CVS also believes that expanding the scope and role of Registered Veterinary Nurses to undertake a wider range of procedures is long overdue.

 

CVS understands the consultation will last for eight weeks and looks forward to continuing its dialogue with DEFRA, and to sharing its thoughts during the consultation.

 

The Group continues to expect to deliver FY2026 results in line with the Board's expectations.

 

Paul Higgs, Chief Veterinary Officer commented: "The Veterinary Profession has been calling for reform of the outdated Veterinary Surgeons Act for over a decade, something CVS continues to be supportive of. We are pleased to see the Government take the opportunity of the CMA investigation to accelerate this process."

 

 

Contacts

CVS Group plc via Camarco

Richard Fairman, CEO

Robin Alfonso, CFO

Paul Higgs, Chief Veterinary Officer

Charlotte Page, Head of Investor Relations

 

Berenberg (Joint Broker) +44 (0)20 3207 7800

Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing

 

Peel Hunt LLP (Nominated Adviser & Joint Broker) +44 (0)20 7418 8900

Christopher Golden / James Steel / Andrew Clark

 

Camarco (Financial PR) [email protected]

Ginny Pulbrook +44 (0)7961 315 138

Letaba Rimell

Tilly Butcher

 

About CVS Group plc (www.cvsukltd.co.uk)

 

CVS Group is a leading provider of veterinary services with operations in the UK and Australia. CVSG is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical and support teams at the core of its strategy.

 

The Group now operates c.470 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVSG operates Laboratories (providing diagnostic services to CVSG and third-parties) and an Online Retail Business.

 

The Group employs c.8,900 personnel, including c.2,500 veterinary surgeons and c.3,300 nurses and patient care assistants.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RSPFIFIDLEITFIR

Related Shares:

CVS Group
FTSE 100 Latest
Value10,223.54
Change51.78